@sexedtok's TRT claims need more context, we found

What did @sexedtok actually say?

The creator walked through a clinical decision tree for erectile dysfunction: when oral medications like Viagra and Cialis aren't cutting it, the next option is intracavernosal injections, meaning shots directly into the erectile tissue of the penis. They named the agents involved: Prostaglandin E1, papaverine, and phentolamine. Their core claim is that these are "arterial dilators" that expand blood vessels in the penis and produce harder erections. That's a reasonable, mostly accurate summary of how ICI therapy works in clinical practice. Credit where it's due: this is a legitimate second-line therapy, not fringe medicine.

The creator frames this as a provider explaining options to a patient, which keeps it educational rather than prescriptive. For an 8-second TikTok explainer, the core science here is largely sound.

Does the science back this up?

Yes, with some important nuance. Intracavernosal injection therapy is well-documented and endorsed by the American Urological Association as a second-line treatment for ED. Alprostadil (Prostaglandin E1) has the most strong evidence base. Hatzimouratidis et al. (2010, European Urology) confirmed response rates between 70-80% in men with organic ED who didn't respond adequately to PDE5 inhibitors.

The combination product the creator refers to as "papavarin and phantolamine" is almost certainly bi-mix or a component of tri-mix, a compounded formulation combining papaverine, phentolamine, and sometimes alprostadil. Bella et al. (2007, Journal of Sexual Medicine) found tri-mix to be effective in men with severe vascular ED where monotherapy failed. Papaverine is a nonselective phosphodiesterase inhibitor, not strictly an arterial dilator in the same class as the others, but the net effect on penile blood flow is similar enough that the creator's shorthand isn't wrong.

What did they get wrong (or right)?

Mostly right on the pharmacology, but the mechanism description is a bit loose. Calling all three agents "arterial dilators" is an oversimplification. Papaverine works primarily by inhibiting phosphodiesterase enzymes, which relaxes smooth muscle through a different pathway than direct arterial dilation. Phentolamine is an alpha-adrenergic blocker, not a vasodilator in the traditional sense. Alprostadil (PGE1) does act more directly on vascular smooth muscle via adenylyl cyclase. These distinctions matter for understanding side effect profiles and contraindications, even if the end result, more blood into the corpus cavernosum, is the same.

The creator also mispronounced phentolamine as "phantolamine," which is minor but worth noting for anyone trying to look this up. More importantly, they didn't mention the significant side effect profile: priapism (prolonged, painful erection) is a real risk with ICI therapy, occurring in roughly 1-5% of users according to Montague et al. (2010, Journal of Urology). That omission isn't a dealbreaker for a short video, but it's a gap.

What should you actually know?

If oral ED medications haven't worked for you, ICI therapy is a legitimate, evidence-backed option, not a last resort and not experimental. But it's not something to self-administer without proper training and a prescription. These are compounded medications in most cases, which means formulation and potency can vary between pharmacies. That variability matters clinically.

The starting dose and titration for ICI therapy should happen in a clinical setting specifically to avoid priapism, which is a medical emergency if it lasts more than four hours. Any erection lasting longer than that requires immediate medical attention. Hsieh et al. (2012, Asian Journal of Andrology) found that in-office dose titration significantly reduced the risk of priapism compared to starting at home.

ICI therapy also has a dropout rate. Patient satisfaction is high among those who continue, but roughly 30-50% of men discontinue within the first year due to injection anxiety, pain, or partner discomfort, per Wespes et al. (2002, European Urology). That's a real consideration worth discussing with a provider.